Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Sunny skies and cool breezes are enveloping the Pharmalot campus, where the short person is, once again, hovering over a laptop and the official mascot is happily snoozing in a corner. All of which means we are able to focus on the tasks at hand. First up is brewing another cup of stimulation. Our choice today is cinnamon dolce. Feel free to join us. Meanwhile, here are a few items of interest to get you going. We hope today is productive and enjoyable. Meanwhile, stay in touch and stay safe — wear a mask. …

Food and Drug Administration Commissioner Stephen Hahn defended his agency’s vetting process for the Pfizer (PFE) Covid-19 vaccine, saying a thorough and meticulous review is needed to assure a skeptical public of safety and effectiveness, The Wall Street Journal tells us. Hahn maintained the agency has had 150 people working days, nights and weekends in parallel teams to review the test data submitted. His comments came on the day that U.K. regulators cleared the Pfizer vaccine for general distribution.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • A cynic might observe (although not this writer) that sending the boss to HHS has paid off handsomely for Lilly? Those two purchases seem to roughly total over $1.S Billion USD.

Comments are closed.